CD4+ T cells and natural killer cells: Biomarkers for hepatic fibrosis in human immunodeficiency virus/hepatitis C virus-coinfected patients

Table 1 Fluorochrome-conjugated antibodies panels

Antibody	Fluorochrome	Clone	Provider
All panels
Anti-CD3	APC/Cy7	SK7	BioLegend
Anti-CD56	PE/Cy5	679.1Mc7	Beckman Coulter
Panel 1
Anti-CD57	APC	HNK-1	BioLegend
Anti-CD25	PE	BC96	BioLegend
Anti-CD69	FITC	FN50	BioLegend
Panel 2
Anti-NKp30	PE	P30-15	Biolegend
Anti-NKp46	PE/Cy7	9E2	Biolegend
Anti-NKG2D	APC	1D11	Biolegend
Anti-DNAM	FITC	TX25	Biolegend
Panel 3
Anti-CD62L	PE/Cy7	DREG-56	Biolegend
Anti-CCR7	PE	G043H7	Biolegend
Panel 4
Anti-TRAIL	PE	S35-934	BD Bioscience
Panel 5
Anti-FasL	PE	NOK-1	Biolegend
Anti CD94	FITC	DX22	Biolegend

BioLegend, San Diego, California United States. BD Bioscience, San Jose, California, United States. NK: Natural killer.

Table 2 Characteristics of the population and divided according the level of fibrosis

Characteristics	Group 1	Group 2	Control	P value
	n = 11	n = 13	n = 5
Age (yr)1	46.3 (3.9)	52.2 (4.5)	31 (4.8)	0.02
Male/female	9/2	11/2	3/2	0.85
CD4 cell count1	770 (205)	521 (312)	910 (251)	0.03
CD8 cell count1	1079 (475)	657 (339)	NA	0.24
METAVIR F0-F2	100%	0	100%	NC
METAVIR F3-F4	0	100%	0	NC
TGP1	79.7 (74.2)	99 (71.4)	NA	0.41
Time of known HIV infection1	18 (6.52)	17.3 (3.8)	NC	0.60
Time of known HCV infection1	14.3 (7.0)	13.8 (4.6)	NC	0.65

¹mean ± SD. Beckman Coulter, Marseille, France. P values, correspond to comparison between group 1 and 2. NA: Not available; NC: Not correspond; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus.